On the public citation graph
Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study
0 signed · 178 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.291.15.1864openalex-snapshot
Lipid-Lowering Therapy With Statins in High-Risk Elderly Patients
inferredcites →https://doi.org/10.1001/jama.294.10.1240openalex-snapshot
Risk-Treatment Mismatch in the Pharmacotherapy of Heart Failure
inferredcites →https://doi.org/10.1001/jamainternmed.2014.5294openalex-snapshot
Initial Choice of Oral Glucose-Lowering Medication for Diabetes Mellitus
inferredcites →https://doi.org/10.1002/pds.4377openalex-snapshot
Validation of an algorithm for identifying type 1 diabetes in adults based on electronic health record data
inferredcites →https://doi.org/10.1007/s11892-018-1018-0openalex-snapshot
Hypoglycemia Among Patients with Type 2 Diabetes: Epidemiology, Risk Factors, and Prevention Strategies
inferredcites →https://doi.org/10.1007/s40615-016-0320-2openalex-snapshot
Racial-Ethnic Disparities in Uptake of New Hepatitis C Drugs in Medicare
inferredcites →https://doi.org/10.1016/0021-9681(87)90171-8openalex-snapshot
A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
inferredcites →https://doi.org/10.1016/j.amjmed.2003.08.025openalex-snapshot
Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?
inferredcites →https://doi.org/10.1016/j.cardfail.2019.05.007openalex-snapshot
Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America
inferredcites →https://doi.org/10.1016/j.diabet.2018.02.001openalex-snapshot
Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials
inferredcites →https://doi.org/10.1016/j.jclinepi.2004.06.002openalex-snapshot
A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors
inferredcites →https://doi.org/10.1016/j.numecd.2017.10.011openalex-snapshot
Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database
inferredcites →https://doi.org/10.1056/nejmoa1504720openalex-snapshot
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1515920openalex-snapshot
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1611925openalex-snapshot
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1812389openalex-snapshot
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
inferredcites →https://doi.org/10.1097/00005650-200308000-00004openalex-snapshot
Physician and Practice Characteristics Associated with the Early Utilization of New Prescription Drugs
inferredcites →https://doi.org/10.1097/mlr.0000000000000549openalex-snapshot
Who Were the Early Adopters of Dabigatran?
inferredcites →https://doi.org/10.1111/dom.12494openalex-snapshot
Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial ( EASE ‐1)
inferredcites →https://doi.org/10.1111/ecc.13648openalex-snapshot
Validating the adapted Diabetes Complications Severity Index in claims data.
inferredcites →https://doi.org/10.1111/j.1365-2710.2005.00627.xopenalex-snapshot
Adoption of celecoxib and rofecoxib: a nationwide database study
inferredcites →https://doi.org/10.1111/j.1475-6773.2006.00682.xopenalex-snapshot
Utilizing New Prescription Drugs: Disparities among Non‐Hispanic Whites, Non‐Hispanic Blacks, and Hispanic Whites
inferredcites →https://doi.org/10.1161/cir.0000000000000691openalex-snapshot
Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update
inferredcites →https://doi.org/10.1161/circulationaha.113.005081openalex-snapshot
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
inferredcites →https://doi.org/10.1161/circulationaha.117.031227openalex-snapshot
Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor
inferredcites →https://doi.org/10.1186/1472-6963-12-56openalex-snapshot
Adoption of new drugs by physicians: a survival analysis
inferredcites →https://doi.org/10.1186/s40200-015-0210-xopenalex-snapshot
Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
inferredcites →https://doi.org/10.1210/jc.2015-1860openalex-snapshot
Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
inferredcites →https://doi.org/10.1210/jc.2015-3167openalex-snapshot
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.1371/journal.pone.0141085openalex-snapshot
Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes
inferredcites →https://doi.org/10.1377/hlthaff.2014.0038openalex-snapshot
Optum Labs: Building A Novel Node In The Learning Health Care System
inferredcites →https://doi.org/10.2165/00002512-200623010-00007openalex-snapshot
The Effect of Direct-to-Consumer Advertising on Prescription Drug Use by Older Adults
inferredcites →https://doi.org/10.2337/dc12-0964openalex-snapshot
Automated Detection and Classification of Type 1 Versus Type 2 Diabetes Using Electronic Health Record Data
inferredcites →https://doi.org/10.2337/dc13-2338openalex-snapshot
Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial
inferredcites →https://doi.org/10.2337/dc13-2955openalex-snapshot
Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
inferredcites →https://doi.org/10.2337/dc14-2142openalex-snapshot
Trends in the Evidence Level for the American Diabetes Association's “Standards of Medical Care in Diabetes” From 2005 to 2014
inferredcites →https://doi.org/10.2337/dc14-2806openalex-snapshot
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
inferredcites →https://doi.org/10.2337/dc14-s014openalex-snapshot
Standards of Medical Care in Diabetes—2014
inferredcites →https://doi.org/10.2337/dc15-0843openalex-snapshot
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
inferredcites →https://doi.org/10.2337/dc15-1251openalex-snapshot
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
inferredcites →https://doi.org/10.2337/dc15-1730openalex-snapshot
Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
inferredcites →https://doi.org/10.2337/dc16-0985openalex-snapshot
Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013
inferredcites →https://doi.org/10.2337/dc17-1414openalex-snapshot
Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc19-s004openalex-snapshot
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2019
inferredcites →https://doi.org/10.2337/dc19-s009openalex-snapshot
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
inferredcites →https://doi.org/10.2337/dci18-0007openalex-snapshot
Economic Costs of Diabetes in the U.S. in 2017
inferredcites →https://doi.org/10.2337/dci18-0033openalex-snapshot
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
inferredcites →https://doi.org/10.2337/diacare.26.3.917openalex-snapshot
Economic Costs of Diabetes in the U.S. in 2002
inferredcites →https://doi.org/10.2337/diacare.27.8.1879openalex-snapshot
The Incidence of Congestive Heart Failure in Type 2 Diabetes
inferredcites →https://doi.org/10.2337/diacare.29.02.06.dc05-1593openalex-snapshot
Standards of Medical Care in Diabetes
inferredcites →https://doi.org/10.4158/cs-2018-0535openalex-snapshot
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary
inferredcites →https://doi.org/10.4158/ep13176.csopenalex-snapshot
American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary
inferredcites →https://doi.org/10.4158/ep151016.oropenalex-snapshot
Glycemic Effects Of Sglt-2 Inhibitor Canagliflozin In Type 1 Diabetes Patients Using The Dexcom G4 Platinum Cgm
inferredcites →https://doi.org/10.4158/ep151126.csopenalex-snapshot
Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY
inferredcites →https://doi.org/10.4158/ep15672.glopenalex-snapshot
American Association of Clinical Endocrinologists and American College of Endocrinology – Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan – 2015 — Executive Summary
inferredcites →https://doi.org/10.4158/ep15672.glsupplopenalex-snapshot
American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan – 2015
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4688427openalex-extracted
Effects of Sglt2 Inhibitors on Cardiac Mechanics in Hispanic and Black Diabetic Patients Without Cardiovascular Diseases
inferred← citeshttps://doi.org/10.2139/ssrn.4822553openalex-extracted
A Bibliometric Analysis of Comorbidity of Heart Failure and Type 2 Diabetes in 2015-2024
inferred← citeshttps://doi.org/10.1001/jamainternmed.2021.7457openalex-snapshot
Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2020.35792openalex-snapshot
Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.17886openalex-snapshot
Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease
inferred← citeshttps://doi.org/10.1002/edm2.245openalex-snapshot
Compared to commercially insured patients, Medicare advantage patients adopt newer diabetes drugs more slowly and adhere to them less
inferred← citeshttps://doi.org/10.1002/ehf2.13811openalex-snapshot
Egyptian Expert Opinion for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction
inferred← citeshttps://doi.org/10.1002/pds.5192openalex-snapshot
SGLT ‐2 inhibitors and the risk of hospitalization for community‐acquired pneumonia: A population‐based cohort study
inferred← citeshttps://doi.org/10.1002/phar.70030openalex-snapshot
Heterogeneous effects of sodium–glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors on nephrolithiasis in older adults with type 2 diabetes
inferred← citeshttps://doi.org/10.1007/s00018-022-04289-zopenalex-snapshot
Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin
inferred← citeshttps://doi.org/10.1007/s10557-022-07403-2openalex-snapshot
Inadequate Use of Newer Treatments and Glycemic Control by Cardiovascular Risk and Sociodemographic Groups in US Adults with Diabetes in the NIH Precision Medicine Initiative All of Us Research Program
inferred← citeshttps://doi.org/10.1007/s11096-024-01828-5openalex-snapshot
Evaluating the appropriateness and the factors associated with sodium-glucose co-transporter 2 inhibitors prescribing in a Middle Eastern country: a cross-sectional study
inferred← citeshttps://doi.org/10.1007/s11606-021-07157-xopenalex-snapshot
HbA1c-Triggered Endocrinology Electronic Consultation for Type 2 Diabetes Management
inferred← citeshttps://doi.org/10.1007/s11606-021-07331-1openalex-snapshot
Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System
inferred← citeshttps://doi.org/10.1007/s11606-022-07863-0openalex-snapshot
Care Gaps in Sodium-Glucose Cotransporter-2 Inhibitor and Renin Angiotensin System Inhibitor Prescriptions for Patients with Diabetic Kidney Disease
inferred← citeshttps://doi.org/10.1007/s11606-024-08961-xopenalex-snapshot
Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study
inferred← citeshttps://doi.org/10.1007/s11606-025-09784-0openalex-snapshot
Fill Patterns of Glucose-Lowering Drugs with Cardiovascular and Kidney Benefits in the Rural and Urban United States, 2012–2021
inferred← citeshttps://doi.org/10.1007/s11606-026-10178-zopenalex-snapshot
Association of Social Determinants of Health with Utilization of SGLT2 Inhibitors and GLP1 Receptor Agonists: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1007/s11886-021-01503-5openalex-snapshot
Quality of Diabetes Care in the USA
inferred← citeshttps://doi.org/10.1007/s11886-022-01694-5openalex-snapshot
A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents?
inferred← citeshttps://doi.org/10.1007/s11886-026-02431-yopenalex-snapshot
Disparities in GLP-1RA and SGLT2i Uptake: a Systematic Review and an Equity-First Framework for Cardiovascular-Kidney-Metabolic Care
inferred← citeshttps://doi.org/10.1007/s12020-021-02710-4openalex-snapshot
Race and sex differences in the initiation of diabetes drugs by privately insured US adults
inferred← citeshttps://doi.org/10.1007/s12325-020-01405-yopenalex-snapshot
Primary Care Physicians’ Knowledge of the Cardiovascular Effects of Diabetes Medications: Findings from an Online Survey
inferred← citeshttps://doi.org/10.1007/s13300-021-01137-4openalex-snapshot
Identification of the Inappropriate Clinical Actions (DON'T) to Improve the Management of Patients with Type 2 Diabetes Failing Basal Insulin Supported Oral Treatment: Results of Survey for a Panel of Diabetes Specialists in Italy
inferred← citeshttps://doi.org/10.1007/s13300-022-01237-9openalex-snapshot
Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
inferred← citeshttps://doi.org/10.1007/s13300-022-01280-6openalex-snapshot
Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
inferred← citeshttps://doi.org/10.1007/s13340-026-00899-1openalex-snapshot
Trends in sodium–glucose transport protein 2 inhibitor prescriptions: application of the ATC/DDD system to NDB open data
inferred← citeshttps://doi.org/10.1007/s40615-025-02410-zopenalex-snapshot
Evidence-Based Practice in Prescribing SGLT2i and GLP-1 RA Across Ethnic and Racial Groups: a Systematic Review and Meta-analysis of Observational Studies
inferred← citeshttps://doi.org/10.1016/j.aed.2026.03.012openalex-snapshot
Trends in Sodium–Glucose Cotransporter 2 Inhibitor and Glucagon‑Like Peptide‑1 Receptor Agonist Prescription Rates Among Patients With Type 2 Diabetes: An Epic Cosmos Real-World Data Analysis, 2014-2024
inferred← citeshttps://doi.org/10.1016/j.ajpc.2023.100477openalex-snapshot
Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
inferred← citeshttps://doi.org/10.1016/j.amjcard.2021.11.013openalex-snapshot
Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization
inferred← citeshttps://doi.org/10.1016/j.diabres.2021.108825openalex-snapshot
Correlates of analog vs human basal insulin use among individuals with type 2 diabetes: A cross-sectional study
inferred← citeshttps://doi.org/10.1016/j.diabres.2022.109855openalex-snapshot
Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.diabres.2022.110233openalex-snapshot
Disparities in adoption of new diabetic therapies with cardiovascular benefits
inferred← citeshttps://doi.org/10.1016/j.diabres.2025.112039openalex-snapshot
Patient and physician factors driving the gaps in use of drugs with cardiovascular and kidney benefits by medicare beneficiaries with type 2 diabetes treated by endocrinologists, nephrologists, and cardiologists: Population-based cohort study
inferred← citeshttps://doi.org/10.1016/j.ekir.2021.08.018openalex-snapshot
Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD
inferred← citeshttps://doi.org/10.1016/j.hlc.2025.05.095openalex-snapshot
Implementation Barriers to Evidence-Based Cardiovascular-Kidney-Metabolic Syndrome Management
inferred← citeshttps://doi.org/10.1016/j.ijcard.2025.133079openalex-snapshot
Racial and regional differences in efficacy of sodium-glucose cotransporter 2 inhibitors on cardiorenal outcomes: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.japh.2021.10.007openalex-snapshot
Impact of a clinical pharmacist on provider prescribing patterns in a primary care clinic
inferred← citeshttps://doi.org/10.1016/j.japh.2023.10.010openalex-snapshot
Prevalence of sodium-glucose transporter 2 inhibitor-associated diabetic ketoacidosis in real-world data: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.jchf.2022.11.014openalex-snapshot
Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
inferred← citeshttps://doi.org/10.1016/j.jchf.2023.03.025openalex-snapshot
Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk
inferred← citeshttps://doi.org/10.1016/j.jdiacomp.2021.107972openalex-snapshot
Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study
inferred← citeshttps://doi.org/10.1016/j.numecd.2023.10.012openalex-snapshot
Carnosine supplementation improves glucose control in adults with pre-diabetes and type 2 diabetes: A randomised controlled trial
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2024.108752openalex-snapshot
New drug discovery and development from natural products: Advances and strategies
inferred← citeshttps://doi.org/10.1016/j.xkme.2022.100446openalex-snapshot
Increasing Sodium-Glucose Cotransporter 2 Inhibitor Use in CKD: Perspectives and Presentation of a Clinical Pathway
inferred← citeshttps://doi.org/10.1016/j.xkme.2022.100564openalex-snapshot
Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States
inferred← citeshttps://doi.org/10.1016/s2213-8587(20)30343-0openalex-snapshot
Guideline recommendations and the positioning of newer drugs in type 2 diabetes care
inferred← citeshttps://doi.org/10.1080/14656566.2025.2504702openalex-snapshot
The contemporary landscape of cardiovascular optimization in type 2 diabetes: overcoming barriers to evidence-based use of newer antihyperglycemic agents
inferred← citeshttps://doi.org/10.1093/eurjpc/zwag367openalex-snapshot
Obesity and cardiovascular outcomes after myocardial infarction: a nationwide SWEDEHEART analysis by diabetes status
inferred← citeshttps://doi.org/10.1093/qje/qjad036openalex-snapshot
Representation and Extrapolation: Evidence from Clinical Trials
inferred← citeshttps://doi.org/10.1097/jac.0000000000000379openalex-snapshot
Cardiovascular Disease in Patients With Type 2 Diabetes
inferred← citeshttps://doi.org/10.1097/md.0000000000023489openalex-snapshot
Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region
inferred← citeshttps://doi.org/10.1101/2022.12.27.22283968openalex-snapshot
Multinational Patterns of Second-line Anti-hyperglycemic Drug Initiation Across Cardiovascular Risk Groups: A Federated Pharmacoepidemiologic Evaluation in LEGEND-T2DM
inferred← citeshttps://doi.org/10.1111/dom.13929openalex-snapshot
The present and future scope of real‐world evidence research in diabetes: What questions can and cannot be answered and what might be possible in the future?
inferred← citeshttps://doi.org/10.1111/dom.14245openalex-snapshot
Real‐world use of cardioprotective glucose‐lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019
inferred← citeshttps://doi.org/10.1111/dom.14684openalex-snapshot
Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice
inferred← citeshttps://doi.org/10.1111/dom.14708openalex-snapshot
Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors among patients with type 2 diabetes with and without established cardiovascular diseases: A model‐based simulation analysis using 10‐year real‐world data and targeted literature review
inferred← citeshttps://doi.org/10.1111/dom.15691openalex-snapshot
Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof‐of‐concept results from the DECIDE ‐ CV clinical programme
inferred← citeshttps://doi.org/10.1111/dom.15943openalex-snapshot
Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes
inferred← citeshttps://doi.org/10.1111/jphs.12373openalex-snapshot
Health expenditure and health services utilization comparison of patients with type 2 diabetes on sodium–glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: evidence from 2015 to 2016 medical expenditure panel survey
inferred← citeshttps://doi.org/10.1136/bmjdrc-2019-001007openalex-snapshot
Paradox of glycemic management: multimorbidity, glycemic control, and high-risk medication use among adults with diabetes
inferred← citeshttps://doi.org/10.1136/bmjdrc-2020-001279openalex-snapshot
Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012–2018
inferred← citeshttps://doi.org/10.1136/bmjdrc-2020-001878openalex-snapshot
Development and evaluation of a patient-centered quality indicator for the appropriateness of type 2 diabetes management
inferred← citeshttps://doi.org/10.1136/bmjdrc-2025-005546openalex-snapshot
Low uptake and disparities in therapeutic inertia of cardiorenal protective diabetes medications for patients with type 2 diabetes and above-target hemoglobin A1c
inferred← citeshttps://doi.org/10.1136/bmjmed-2022-000419openalex-snapshot
Comparative effectiveness of second line glucose lowering drug treatments using real world data: emulation of a target trial
inferred← citeshttps://doi.org/10.1136/bmjmed-2023-000651openalex-snapshot
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM
inferred← citeshttps://doi.org/10.1136/bmjopen-2021-057977openalex-snapshot
Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies
inferred← citeshttps://doi.org/10.1159/000526254openalex-snapshot
Age-Related Association between Multimorbidity and Mortality in US Veterans with Incident Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1161/cir.0000000000000920openalex-snapshot
Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association
inferred← citeshttps://doi.org/10.1161/circheartfailure.120.007264openalex-snapshot
Understanding the Complexity of Heart Failure Risk and Treatment in Black Patients
inferred← citeshttps://doi.org/10.1161/circoutcomes.120.007264openalex-snapshot
Cardio-Renal-Metabolic Care Models
inferred← citeshttps://doi.org/10.1161/circulationaha.120.052821openalex-snapshot
Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Racial Differences and a Potential for Reducing Disparities
inferred← citeshttps://doi.org/10.1161/jaha.120.019331openalex-snapshot
Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease
inferred← citeshttps://doi.org/10.1161/jaha.124.040217openalex-snapshot
Heterogeneity of Cardiovascular Effects of Second‐Line Glucose‐Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk
inferred← citeshttps://doi.org/10.1177/08971900241247658openalex-snapshot
Impact of American Diabetes Association 2022 Guidelines on Prescribing Rates of Sodium-Glucose Cotransporter-2 Inhibitors in Ambulatory Care Organization Patients With Type 2 Diabetes
inferred← citeshttps://doi.org/10.1177/2042018820980225openalex-snapshot
Should metformin remain the first-line therapy for treatment of type 2 diabetes?
inferred← citeshttps://doi.org/10.1177/2054358120935701openalex-snapshot
Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review
inferred← citeshttps://doi.org/10.1186/s12875-022-01731-wopenalex-snapshot
Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study
inferred← citeshttps://doi.org/10.1186/s12875-022-01928-zopenalex-snapshot
Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study
inferred← citeshttps://doi.org/10.1186/s12877-022-02792-3openalex-snapshot
Initiating second-line antidiabetic medication among older adults with type 2 diabetes on Metformin
inferred← citeshttps://doi.org/10.1186/s12882-021-02381-3openalex-snapshot
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
inferred← citeshttps://doi.org/10.1186/s12933-024-02365-1openalex-snapshot
Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease
inferred← citeshttps://doi.org/10.1186/s43058-021-00145-6openalex-snapshot
Increasing risk-concordant cardiovascular care in diverse health systems: a mixed methods pragmatic stepped wedge cluster randomized implementation trial of shared decision making (SDM4IP)
inferred← citeshttps://doi.org/10.1212/cpj.0000000000200101openalex-snapshot
Racial and Ethnic Differences in Antiseizure Medications Among People With Epilepsy on Medicaid
inferred← citeshttps://doi.org/10.12788/fp.0148openalex-snapshot
Preoperative Care Assessment of Need Scores Are Associated With Postoperative Mortality and Length of Stay in Veterans Undergoing Knee Replacement
inferred← citeshttps://doi.org/10.12968/jprp.2021.3.5.176openalex-snapshot
Diabetes care: a time to review prescribing approaches and reach out to local communities
inferred← citeshttps://doi.org/10.1371/journal.pone.0271740openalex-snapshot
Evaluation of the clinical utility of the PromarkerD in-vitro test in predicting diabetic kidney disease and rapid renal decline through a conjoint analysis
inferred← citeshttps://doi.org/10.1371/journal.pone.0287599openalex-snapshot
Sex and age differences in the use of medications for diabetes and cardiovascular risk factors among 25,733 people with diabetes
inferred← citeshttps://doi.org/10.15226/2374-6890/9/1/001155openalex-snapshot
Beyond The Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
inferred← citeshttps://doi.org/10.1536/ihj.20-716openalex-snapshot
Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan
inferred← citeshttps://doi.org/10.15420/cfr.2022.08openalex-snapshot
In-hospital Initiation and Up-titration of Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction
inferred← citeshttps://doi.org/10.15605/jafes.040.02.22openalex-snapshot
Sodium-Glucose Cotransporter-2 inhibitor (SGLT2i) Prescription Rates Amongst Diabetologists for Type 2 Diabetes Patients with Albuminuric Diabetic Kidney Disease:
inferred← citeshttps://doi.org/10.1681/nsap.00042022openalex-snapshot
Epidemiology and Outcomes for the Chronic Kidney Disease
inferred← citeshttps://doi.org/10.18553/jmcp.2023.29.11.1242openalex-snapshot
Individual and social determinants of adherence to sodium-glucose cotransporter 2 inhibitor therapy: A trajectory analysis
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1126975/v1openalex-snapshot
Cost-Effectiveness of SGLT2is Versus DPP4is Among Type 2 Diabetes Patients with and Without Established Cardiovascular Disease: A Model-Based Simulation Analysis Using 10-Year Real-World Data and Systematic Review
inferred← citeshttps://doi.org/10.2147/ijnrd.s430532openalex-snapshot
Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective
inferred← citeshttps://doi.org/10.2196/29286openalex-snapshot
Leveraging National Claims and Hospital Big Data: Cohort Study on a Statin-Drug Interaction Use Case
inferred← citeshttps://doi.org/10.2337/cd24-0007openalex-snapshot
Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk
inferred← citeshttps://doi.org/10.2337/dc20-0735openalex-snapshot
Medicaid Expansion and Utilization of Antihyperglycemic Therapies
inferred← citeshttps://doi.org/10.2337/dc20-2977openalex-snapshot
Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities
inferred← citeshttps://doi.org/10.2337/dc23-1652openalex-snapshot
Disparities in Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Prescription and Dispensing in the Israeli Population—A Retrospective Cohort Study
inferred← citeshttps://doi.org/10.24875/nefro.m24000037openalex-snapshot
Documento de consenso sobre nuevas terapias para retrasar la progresión de la enfermedad renal crónica con énfasis en los iSGLT-2: implicaciones para Latinoamérica
inferred← citeshttps://doi.org/10.3389/fendo.2026.1929125openalex-snapshot
Knowledge, attitudes, and practices of Saudi physicians toward the use of SGLT-2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus: a nationwide cross-sectional study
inferred← citeshttps://doi.org/10.3390/biomedicines13081924openalex-snapshot
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome
inferred← citeshttps://doi.org/10.3390/ijerph20054036openalex-snapshot
Impact of Contextual-Level Social Determinants of Health on Newer Antidiabetic Drug Adoption in Patients with Type 2 Diabetes
inferred← citeshttps://doi.org/10.3390/jcm13051367openalex-snapshot
Type 2 Diabetes and Chronic Kidney Disease: An Opportunity for Pharmacists to Improve Outcomes
inferred← citeshttps://doi.org/10.3390/jcm13154555openalex-snapshot
Effects of SGLT2 Inhibitors on Cardiac Mechanics in Hispanic and Black Diabetic Patients
inferred← citeshttps://doi.org/10.3390/medicina59020388openalex-snapshot
SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
inferred← citeshttps://doi.org/10.3390/ph18060807openalex-snapshot
Evaluating Guideline Alignment by Analyzing Patient Profiles of Elderly People with Type 2 Diabetes and Chronic Kidney Disease Treated or Not with SGLT2 Inhibitors
inferred← citeshttps://doi.org/10.3390/pharmacy13020046openalex-snapshot
Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence
inferred← citeshttps://doi.org/10.3399/bjgp20x714089openalex-snapshot
Trends in diabetes medication use in Australia, Canada, England, and Scotland: a repeated cross-sectional analysis in primary care
inferred← citeshttps://doi.org/10.34067/kid.0000412021openalex-snapshot
Real-Life Prescribing of SGLT2 Inhibitors: How to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics
inferred← citeshttps://doi.org/10.35841/1836-1935.13.1.16-25openalex-snapshot
Dapagliflozin effects on hospitalization for heart failure reduction, and major adverse cardiovascular events
inferred← citeshttps://doi.org/10.4093/dmj.2022.0002openalex-snapshot
Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease
inferred← citeshttps://doi.org/10.6084/m9.figshare.14600443openalex-snapshot
Additional file 1 of Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
inferred← citeshttps://doi.org/10.6084/m9.figshare.19844661openalex-snapshot
Additional file 1 of Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study
inferred← citeshttps://doi.org/10.6084/m9.figshare.19844664openalex-snapshot
Additional file 2 of Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study
inferred← citeshttps://doi.org/10.6084/m9.figshare.26758622openalex-snapshot
Additional file 1 of Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease
inferred← citeshttps://doi.org/10.7326/m22-3635openalex-snapshot
2022 Clinical Practice Guideline Update for Diabetes Management of Chronic Kidney Disease: An Important First Step, More Work to Do
inferred← citeshttps://doi.org/10.7759/cureus.104564openalex-snapshot
Beyond Glucose Control: A Comprehensive Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Heart Failure, Chronic Kidney Disease, and Nonalcoholic Fatty Liver Disease
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.